Nishant Das
Independent Researcher
West Bengal, India
Abstract
Transparency and accountability are crucial components in clinical research to maintain public trust and scientific integrity. Despite regulations and ethical oversight, issues such as selective reporting, data tampering, and lack of reproducibility persist in clinical trial conduct. The emergence of blockchain technology offers a decentralized, immutable, and transparent solution to record, store, and share clinical trial data in a tamper-proof environment. This paper explores how blockchain architecture can be utilized to enhance transparency in the clinical trial process, from protocol registration to final data analysis and reporting. A thorough literature review outlines existing challenges in clinical trial documentation and the theoretical foundation of blockchain for healthcare applications. The methodology section presents a prototype model that simulates a blockchain-based clinical trial registry, and results suggest improved traceability and verification potential. This study concludes that blockchain is a promising technological enabler for reforming trial transparency, particularly in regulatory submissions, data access, and public reporting.
Keywords
Blockchain, Clinical Trials, Transparency, Tamper-Proof Ledger, Data Integrity, Distributed System
Blockchain’s Role in Ensuring Transparency in Clinical Trials
Nishant Das
Independent Researcher
West Bengal, India
Abstract
Transparency and accountability are crucial components in clinical research to maintain public trust and scientific integrity. Despite regulations and ethical oversight, issues such as selective reporting, data tampering, and lack of reproducibility persist in clinical trial conduct. The emergence of blockchain technology offers a decentralized, immutable, and transparent solution to record, store, and share clinical trial data in a tamper-proof environment. This paper explores how blockchain architecture can be utilized to enhance transparency in the clinical trial process, from protocol registration to final data analysis and reporting. A thorough literature review outlines existing challenges in clinical trial documentation and the theoretical foundation of blockchain for healthcare applications. The methodology section presents a prototype model that simulates a blockchain-based clinical trial registry, and results suggest improved traceability and verification potential. This study concludes that blockchain is a promising technological enabler for reforming trial transparency, particularly in regulatory submissions, data access, and public reporting.
Keywords
Blockchain, Clinical Trials, Transparency, Tamper-Proof Ledger, Data Integrity, Distributed System
References
- Califf, R. M. (2006). Clinical trials bureaucracy: unintended consequences of well-intentioned policy. Clinical Trials, 3(6), 496–502. https://doi.org/10.1177/1740774506071001
- Chalmers, I. (2006). Protocols, registration, and publication of clinical trials. Lancet, 367(9525), 1631–1633. https://doi.org/10.1016/S0140-6736(06)68708-4
- Dziak, J. J., & Nahum-Shani, I. (2011). Sensitivity and transparency in reporting clinical trial results. Clinical Trials, 8(1), 45–52. https://doi.org/10.1177/1740774510391265
- Eichler, H. G., et al. (2012). Adaptive licensing: Taking the next step in the evolution of drug approval. Clinical Pharmacology & Therapeutics, 91(3), 426–437. https://doi.org/10.1038/clpt.2011.345
- Food and Drug Administration (FDA). (2007). Amendments Act of 2007 (FDAAA 801). U.S. Department of Health and Human Services.
- Gøtzsche, P. C. (2011). Why we need easy access to all data from all clinical trials and how to accomplish it. Trials, 12(1), 249. https://doi.org/10.1186/1745-6215-12-249
- Ioannidis, J. P. A. (2005). Why most published research findings are false. PLoS Medicine, 2(8), e124. https://doi.org/10.1371/journal.pmed.0020124
- Kass, N. E., Taylor, H. A., & Ali, J. (2007). A pilot study of simple interventions to improve informed consent in clinical research: Feasibility, approach, and results. Clinical Trials, 4(6), 632–640. https://doi.org/10.1177/1740774507083437
- Laine, C., Goodman, S. N., Griswold, M. E., & Sox, H. C. (2007). Reproducible research: Moving toward research the public can really trust. Annals of Internal Medicine, 146(6), 450–453. https://doi.org/10.7326/0003-4819-146-6-200703200-00154
- Light, D. W., & Lexchin, J. (2012). Pharmaceutical research and development: What do we get for all that money? BMJ, 345, e4348. https://doi.org/10.1136/bmj.e4348
- Loder, E., Groves, T., Macauley, D., & Glasziou, P. (2013). Registration of observational studies. BMJ, 346, f1756. https://doi.org/10.1136/bmj.f1756
- Milne, C. P., & Bruss, J. B. (2008). The economics of clinical trials. Nature Reviews Drug Discovery, 7(3), 215–216. https://doi.org/10.1038/nrd2504
- Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., … & Altman, D. G. (2010). CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomized trials. BMJ, 340, c869. https://doi.org/10.1136/bmj.c869
- Ross, J. S., Tse, T., Zarin, D. A., Xu, H., Zhou, L., & Krumholz, H. M. (2009). Publication of NIH funded trials registered in ClinicalTrials.gov: Cross-sectional analysis. BMJ, 344, d7292. https://doi.org/10.1136/bmj.d7292